A Phase 1, Open-Label, Multicenter Study of Janx007 in Subjects with Metastatic Castration-Resistant Prostate Cancer

Sponsor:

Janux Therapeutics

Sponsor Study ID:

Janux PSMA-007-001

CTO #:

104144

NCT Number:

NCT05519449

Phase:

I

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Prostate

Study Objectives:

To assess safety and tolerability in subjects with mCRPC to determine the MTD-R or MAD and to assess potential Phase 2 dose regimens and determine a RP2D-R. To assess the safety and tolerability of JANX007 when administered with recombinant human albumin (rHA). To compare the safety and tolerability of 2 potential RP2D-Rs identified from Part 1 and Part 2. To assess the safety and tolerability in taxane naïve subjects with mCRPC.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)